Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yangtze River Pharmaceutical Group To Invest RMB 300 Million In Innovation Projects

This article was originally published in PharmAsia News

Executive Summary

Yangtze River Pharmaceutical Group will invest RMB 300 million to carry out innovative R&D projects this year. The group aims to secure a total of 39 production licenses including nine for class I new drugs, as well as 30 clinical trial permits. It is also filing applications for 24 preclinical research projects. At present, the firm has more than 100 new products under development: new drug iguratimod has entered Phase III trials; yonkenafil will soon complete its Phase I trial; MB-1C is on track to preclinical research; and forsythiaside will receive permission for clinical trials. With focus on establishing an innovation platform, the company is setting up the Jiangsu (Taizhou) New Medicine Research Institute, a national laboratory of pharmaceutical formulation emphasizing new technology and a national engineering research center for TCM pharmaceutical technology. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069932

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel